During a live event, Kathryn E. Beckermann, MD, PhD, and participants discussed their approaches to TKI dose modification and immune checkpoint inhibitor rechallenge in advanced renal cell carcinoma.
Treating Renal Cell Carcinoma With Tyrosine Kinase Inhibition
During a live event, Kathryn E. Beckermann, MD, PhD, and participants discussed whether risk stratification factors into the choice of a combination regimen for advanced renal cell carcinoma.
During a live event, Che-Kai Tsao, MD, MS, and participants considered the tolerability and efficacy benefits of high starting doses vs dose escalation with TKIs in renal cell carcinoma.
During a live event, Che-Kai Tsao, MD, MS, and participants gave their reasoning for their choice of combination therapy for a 65-year-old patient with high-burden metastatic renal cell carcinoma.
Bradley A. McGregor, MD, discusses the challenges shared by oncologists who treat renal cell carcinoma.
Explore the evolving treatment strategies for metastatic clear cell renal cell carcinoma, highlighting innovative combination therapies and their efficacy.
Bradley A. McGregor, MD, discusses the advancements in treating metastatic renal cell carcinoma.
Manojkumar Bupathi, MD, MS, discusses physician perspectives on treatment selection for frontline metastatic renal cell carcinoma (RCC) from a Case-Based Roundtable event.
Manojkumar Bupathi, MD, MS, discussed his takeaways on physician decision-making for frontline metastatic renal cell carcinoma (RCC) treatment from a Case-Based Roundtable event.
During a live event, Daniel M. Geynisman, MD, and participants discussed which efficacy end points they value and how they modify doses of combination renal cell carcinoma therapies.
During a live event, Guru P. Sonpavde, MD discussed improvements to survival with cabozantinib plus nivolumab in metastatic renal cell carcinoma.
During a live event, Guru P. Sonpavde, MD discussed first-line renal cell carcinoma regimens with varying efficacy and toxicity profiles.
During a live event, Daniel M. Geynisman, MD, and participants discussed their answers to a poll on which combination to use for a patient with advanced renal cell carcinoma.
Alan Tan, MD, discusses potential biomarkers that are being investigated to optimize treatment of patients with renal cell carcinoma.
Alan Tan, MD, discusses upcoming trials that could change the landscape of frontline and adjuvant renal cell carcinoma therapy.
Alan Tan, MD, discusses factors influencing the choice of immunotherapy plus tyrosine kinase inhibitor vs dual IO in patients with metastatic renal cell carcinoma.
During a Case-Based Roundtable® event, Daniel J. George, MD, discusses how often community oncology participants see patients with favorable-risk vs intermediate- or high-risk RCC, and how it changes their treatment options.
During a Case-Based Roundtable® event, Daniel J. George, MD and participants discussed combination regimens for intermediate and poor-risk renal cell carcinoma.
During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.
During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or low-volume favorable-risk metastatic clear cell renal cell carcinoma in the first article of a 2-part series.
During a Case-Based Roundtable® event, Rana McKay, MD, discussed the updated data from the CheckMate 9ER trial of patients with advanced renal cell carcinoma in the second article of a 2-part series.
During a Case-Based Roundtable® event, Rana McKay, MD, discussed the updated favorable-risk group data for 4 frontline combination trials in renal cell carcinoma in the first article of a 2-part series.
During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on what factors influence physician decision making for frontline therapy in patients with metastatic renal cell carcinoma in the first article of a 2-part series.
During a Targeted Oncology™ Case-Based Roundtable™ event, Rana McKay, MD, moderated a discussion on key takeaways from frontline combination trial data in patients with metastatic renal cell carcinoma. This is the second of 2 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Rana McKay, MD, moderated a discussion on what role risk stratification plays in selecting frontline therapy for a patient with metastatic renal cell carcinoma. This is the first of 2 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Neeraj Agarwal, MD, discussed his approach to recognizing and managing adverse events related to treatment with cabozantinib and nivolumab in patients with advanced renal cell carcinoma. This is the second article based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Neeraj Agarwal, MD, examined the significance of the 44-month follow-up of the CheckMate 9ER trial of patients with metastatic renal cell carcinoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Benjamin Garmezy, MD, and participants discussed their takeaways from the phase 3 trials of immunotherapy and tyrosine kinase inhibitors in frontline renal cell carcinoma. This is the second article based on this event.
In the first article of a 2-part series, Benjamin Garmezy, MD, discusses risk stratification and combination options in the metastatic clear cell renal cell carcinoma setting.